CCM
ONCY

Cribstone Capital Management’s Oncolytics Biotech ONCY Stock Holding History

Cribstone Capital Management’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-78
Closed – – 691
2018
Q4 		$0 Hold
78
– – ﹤0.01% 739
2018
Q3 		$0 Hold
78
– – ﹤0.01% 791
2018
Q2 		$0 Buy
+78
New +$480 ﹤0.01% 805

Other funds holding ONCY

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
NFG
Next Financial Group Houston, Texas $1.52B AUM 20.14% 1-Year Est. Return

Cribstone Capital Management's ONCY Position: Q1 2019 in Review

Cribstone Capital Management sold out of Oncolytics Biotech (ONCY) in Q1 2019, closing a stake of 78 shares.

Cribstone Capital Management first reported a position in ONCY in Q2 2018 and held it in 3 quarters. The position peaked at $0 in Q4 2018. 22 funds tracked by Wall St. Rank hold ONCY as of Q1 2019.

  • Cribstone Capital Management reported no remaining Oncolytics Biotech position as of Q1 2019 after selling out during the quarter.
  • Cribstone Capital Management sold 78 Oncolytics Biotech shares in Q1 2019.
  • Cribstone Capital Management first reported a position in Oncolytics Biotech in Q2 2018 and held it in 3 quarters.
  • Cribstone Capital Management's Oncolytics Biotech position peaked at $0 in Q4 2018.
  • 22 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q1 2019.

Based on Cribstone Capital Management's 13F filing for Q1 2019, filed 11 Apr 2019.